Ascendis Pharma A/S Announces Publication of Comprehensive Results from Randomized, Active-Controlled Phase 2 Trial of Once-Weekly TransCon Growth Hormone in Pediatric Patients (Ascendis Pharma A/S)
(WorldNews Denmark)

(Source: Ascendis Pharma A/S) COPENHAGEN, Denmark, Feb. 16, 2017 /PRNewswire/ -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs in rare diseases, today announced the publication of its previously presented pediatric phase 2 trial of TransCon Growth Hormone in the Journal of Clinical Endocrinology and Metabolism. The authors concluded that once-weekly, sustained release TransCon Growth Hormone was comparable to daily growth hormone in terms of efficacy, safety and tolerability in children with growth hormone deficiency (GHD). The publication is available online at:...